# Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

> **NCT00959036** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 252 (actual)

## Conditions studied

- Active Rheumatoid Arthritis

## Interventions

- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** ATN-103
- **DRUG:** Placebo
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00959036
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2013-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00959036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00959036, "Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00959036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*